



Biotech Daily

Friday July 13, 2012

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH UP: SUNSHINE HEART UP 9%;**

- GENETIC TECHNOLOGIES DOWN 9%

*** REVA CLOSES REZOLVE PILOT TRIAL – NO MAJOR CORONARY EVENTS**

MARKET REPORT

The Australian stock market climbed 0.35 percent on Friday July 13, 2012 with the S&P ASX 200 up 14.2 points to 4,082.2 points.

Fourteen of the Biotech Daily Top 40 stocks were up, 10 fell, eight traded unchanged and eight were untraded.

Sunshine Heart was the best for the fourth of five trading days, up 0.4 cents or 8.9 percent to 4.9 cents with 3.3 million shares traded, followed by Avita up 8.6 percent to 19 cents with 109,268 shares traded.

Benitec and Prana climbed more than six percent; Living Cell was up 5.8 percent; Clinuvel and Prima were up more than four percent; Anteo rose 2.8 percent; Biota, Mesoblast, Nanosonics and Sirtex were up one percent or more; with Acrux, Cochlear, Heartware and Resmed up by less than one percent.

Genetic Technologies led the falls, down one cent or 9.1 percent to 10 cents with 666,000 shares traded.

Cellmid lost 6.25 percent; both Antisense and Neuren fell 4.2 percent; Bionomics, Phosphagenics and Universal Biosensors were down more than three percent; QRX and Viralytics were down more than one percent; with Alchemia and CSL down by less than one percent.

REVA MEDICAL

Reva says it has completed clinical enrollment of 26 patients in a trial of the Rezolve drug-eluting bio-resorbable scaffold stent.

Reva said the first patient was enrolled in December 2011 and there had been no major adverse coronary events reported to date.

In December 2011, Reva said the trial would be a 50-patient pilot clinical study to evaluate the stent in Brazil and Europe, but recently said shortened the trial to move to a new model sheathless delivery system, called Rezolve2 (BD: Jan 22 , May 18, 2012).

The company said that the data from the 26 would be presented at the Transcatheter Cardiovascular Therapeutics conference, in Miami, Florida in October 2012.

Reva said it would resume clinical trials later in 2012, with the Rezolve2 scaffold, which would be evaluated at up to 25 clinical study sites in Brazil, Europe, Australia and New Zealand.

The Sao Paulo, Brazil-based principal Investigator, Dante Pazzanese Instituto de Cardiologie's Dr Alexandre Abizaid said his group was "very pleased to have implanted the current Rezolve scaffold in patients with no reported [major adverse coronary events] to date and are eager to resume clinical trials with the Rezolve2 scaffold later this year".

Reva was untraded at 58 cents.